Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01758081 · ClinicalTrials.gov registry record · NA

Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18 (VITAL Infection)

A NA study of Infections and Human Cathelicidin Antimicrobial Peptide (hCAP-18), sponsored by Brigham and Women's Hospital.

Active
Registry status
NA
Development phase
25,874
Enrollment target
1
Study location

NCT01758081 is a NA study of Infections and Human Cathelicidin Antimicrobial Peptide (hCAP-18) that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 25,874 participants, above the 2,412-participant average among 26 other Infections trials with a reported enrollment target (973% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01758081, a NA study of Infections and Human Cathelicidin Antimicrobial Peptide (hCAP-18), is active but no longer recruiting, sponsored by Brigham and Women's Hospital.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
25,874 participants
Enrollment target
1
Study location

Study Summary

The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial in 25,875 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study is being conducted among participants in VITAL and will examine whether vitamin D or omega-3 fatty acids affect risk of infection and plasma hCAP18 levels.

Conditions Studied

Infections Human Cathelicidin Antimicrobial Peptide (hCAP-18)

Interventions

  • DIETARY_SUPPLEMENT vitamin D3
  • DIETARY_SUPPLEMENT Vitamin D3 placebo
  • DRUG omega-3 fatty acids (fish oil)
  • DIETARY_SUPPLEMENT fish oil placebo

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 25,874 participants
Start Date 2010-07
Est. Completion 2026-12
Phase NA

Sponsor

Brigham and Women's Hospital

937 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01758081

The ClinicalTrials.gov registry entry for NCT01758081 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 25,874 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,412-participant average among 26 other Infections trials with a reported enrollment target (973% higher). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Infections appearing as the primary indexed condition, and to 4 interventions - of which vitamin D3 is the first listed.

NCT01758081 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01758081 about?

NCT01758081 is a clinical study titled "Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18 (VITAL Infection)". The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial in 25,875 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart dis...

What is the current status of trial NCT01758081?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 25,874 participants. The study started on 2010-07. Estimated completion is 2026-12.

What conditions does trial NCT01758081 study?

This clinical trial studies the following conditions: Infections, Human Cathelicidin Antimicrobial Peptide (hCAP-18).

What interventions are being tested in trial NCT01758081?

The interventions under investigation include: vitamin D3 (DIETARY_SUPPLEMENT), Vitamin D3 placebo (DIETARY_SUPPLEMENT), omega-3 fatty acids (fish oil) (DRUG), fish oil placebo (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01758081?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01758081 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Infections

All registered trials for this condition

Human Cathelicidin Antimicrobial Peptide (hCAP-18)

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.